Some have relabeled it as Pentadecapeptide Aringate or PDA (altering the acetate to an arginate) and therefore are prescribing it for subcutaneous administration like that, even though the confusion about its standing has brought about a lively oral capsule market for BPC in what appears to become a grey area of legality.The downside of BPC-157 is